




# PHARMACEUTICAL 2019

Anixa Biosciences Inc  
Rank 314 of 363





# PHARMACEUTICAL 2019

Anixa Biosciences Inc  
Rank 314 of 363



The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 228% points.

The company's Economic Capital Ratio, given in the ranking table, is -138%, being 175% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	5,538
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,265
Liabilities, Non-Current	0
Other Assets	838
Other Compr. Net Income	0
Other Expenses	1,677
Other Liabilities	0
Other Net Income	46
Other Revenues	1,112
Property and Equipment	73
Research and Development	6,813
Selling, General and Administrative Expense	6,912

Output Variable	Value in 1000 USD
Assets	6,449
Liabilities	1,265
Expenses	15,402
Revenues	1,112
Stockholders Equity	5,183
Net Income	-14,243
Comprehensive Net Income	-14,243
Economic Capital Ratio	-138%